UBS Asset Management Americas Inc. trimmed its holdings in Qiagen NV (NASDAQ:QGEN) by 3.2% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 71,992 shares of the company’s stock after selling 2,403 shares during the quarter. UBS Asset Management Americas Inc.’s holdings in Qiagen were worth $2,227,000 at the end of the most recent quarter.
Several other institutional investors have also added to or reduced their stakes in QGEN. Lourd Capital LLC bought a new position in shares of Qiagen in the fourth quarter valued at about $223,000. Hartford Investment Management Co. bought a new position in shares of Qiagen in the third quarter valued at about $231,000. Trexquant Investment LP acquired a new stake in Qiagen in the third quarter worth about $234,000. Barings LLC acquired a new stake in Qiagen in the third quarter worth about $255,000. Finally, Bronfman E.L. Rothschild L.P. increased its position in Qiagen by 50.8% in the fourth quarter. Bronfman E.L. Rothschild L.P. now owns 11,451 shares of the company’s stock worth $354,000 after purchasing an additional 3,860 shares during the period. 62.23% of the stock is owned by institutional investors and hedge funds.
A number of brokerages recently commented on QGEN. BidaskClub lowered Qiagen from a “buy” rating to a “hold” rating in a research report on Thursday. Zacks Investment Research upgraded Qiagen from a “sell” rating to a “hold” rating in a research report on Tuesday, February 6th. Evercore ISI began coverage on Qiagen in a research report on Wednesday, January 3rd. They issued an “outperform” rating and a $35.00 price objective for the company. Morgan Stanley lifted their price objective on Qiagen from $38.00 to $39.00 and gave the stock an “overweight” rating in a research report on Friday, February 2nd. Finally, Goldman Sachs began coverage on Qiagen in a research report on Monday, January 29th. They issued a “buy” rating and a $39.00 price objective for the company. Nine analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. The stock currently has a consensus rating of “Hold” and a consensus target price of $35.33.
Qiagen (NASDAQ:QGEN) last posted its earnings results on Wednesday, January 31st. The company reported $0.43 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.42 by $0.01. The company had revenue of $396.86 million during the quarter, compared to analyst estimates of $394.48 million. Qiagen had a return on equity of 11.74% and a net margin of 2.85%. equities research analysts predict that Qiagen NV will post 1.34 earnings per share for the current fiscal year.
Qiagen declared that its board has initiated a stock buyback program on Wednesday, January 31st that authorizes the company to buyback $200.00 million in shares. This buyback authorization authorizes the company to purchase shares of its stock through open market purchases. Stock buyback programs are generally a sign that the company’s management believes its shares are undervalued.
QIAGEN N.V. (QIAGEN) is a holding company. The Company is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials.
Receive News & Ratings for Qiagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Qiagen and related companies with MarketBeat.com's FREE daily email newsletter.